Growth and development in paediatric onset inflammatory bowel disease: Data analysis from the CEDATA registry
- 1Department of Paediatrics, Faculty of Medicine and University Hospital Cologne University of Cologne Cologne Germany
- 2General Paediatrics and Neonatology, University Children's Hospital, Justus Liebig University Giessen Giessen Germany
Abstract
Objective: Different therapies may affect the growth and development of children and adolescents with inflammatory bowel disease (IBD) supporting specific therapy algorithms for paediatric Crohn's disease (CD) and ulcerative colitis (UC).
Methods: Growth and development data from the German–Austrian CEDATA‐GPGE registry entered between 2004 and 2021 were analysed for 0–18 year olds with complete follow‐up on diagnoses and therapies. Standard deviation scores (SDS) for height, weight, and body mass index (BMI) were compared between initial diagnosis (t0) and 4‐year follow‐up (t4) within groups using multivariate analysis. Factors included gender, age, disease type, age at diagnosis, and initial therapies.
Results: Data from 450 patients (CD: 303; UC: 147) were analysed. At t0, SDS values for height (mean value [M] = −0.37, standard deviation [SD] = 1.07), weight (M = −0.57, SD = 0.92), and BMI (M = −0.55, SD = 0.95) were below average. The SDS values for weight and BMI increased significantly between t0 and t4 with small effect sizes, whereas the SDS value for height did not. Diagnosis, gender, disease localisation, and remission after 6 months did not influence height SDS. Patients treated exclusively with enteral nutrition (EEN) or azathioprine showed improved weight and BMI development, whereas corticosteroids led to weight gain.
Conclusion: The analysis showed that EEN and disease control significantly improve weight and BMI in children with IBD, SDS‐H catch‐up was only observed in the subgroup with growth impairment at initial diagnosis. Children with severe or recurrent flares, or persistent nutritional deficits, are at increased risk of growth impairment and require close medical monitoring.
Related
- Outcomes and Reclassification Patterns in Inflammatory Bowel Disease Unclassified: A Multicenter Study Matched With Ulcerative Colitis From Spanish ENEIDA Registry
- Development and validation of a novel metabolic-inflammatory health-related nomogram for predicting in-hospital mortality in older patients with type 2 diabetes mellitus combined with cardiovascular disease
- Differences in A1C trajectory by sex and BMI in paediatric type 1 diabetes: a retrospective cohort study using a diabetes registry in British Columbia, Canada
- Pediatric intestinal enteroids derived from very early onset inflammatory bowel disease reveal differences in growth, morphology, and barrier function
- Protocol for the development of a paediatric core outcome set for arthrogryposis multiplex congenita: an international multi-interest-holder consensus study.
BibTeX
@article{schmidt2026growth,
title = {{Growth and development in paediatric onset inflammatory bowel disease: Data analysis from the CEDATA registry}},
author = {Anna Schmidt and Ilse Broekaert and Christoph Hünseler and Jan de Laffolie and CEDATA Study Group},
journal = {Journal of Pediatric Gastroenterology and Nutrition},
year = {2026},
month = aug,
doi = {10.1002/jpn3.70544},
url = {https://doi.org/10.1002/jpn3.70544},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Growth and development in paediatric onset inflammatory bowel disease: Data analysis from the CEDATA registry
AU - Anna Schmidt
AU - Ilse Broekaert
AU - Christoph Hünseler
AU - Jan de Laffolie
AU - CEDATA Study Group
PY - 2026
DA - 2026/08/23
JO - Journal of Pediatric Gastroenterology and Nutrition
DO - 10.1002/jpn3.70544
UR - https://doi.org/10.1002/jpn3.70544
AB - Objective: Different therapies may affect the growth and development of children and adolescents with inflammatory bowel disease (IBD) supporting specific therapy algorithms for paediatric Crohn's disease (CD) and ulcerative colitis (UC). Methods: Growth and development data from the German–Austrian CEDATA‐GPGE registry entered between 2004 and 2021 were analysed for 0–18 year olds with complete follow‐up on diagnoses and therapies. Standard deviation scores (SDS) for height, weight, and body mass index (BMI) were compared between initial diagnosis (t0) and 4‐year follow‐up (t4) within groups using multivariate analysis. Factors included gender, age, disease type, age at diagnosis, and initial therapies. Results: Data from 450 patients (CD: 303; UC: 147) were analysed. At t0, SDS values for height (mean value [M] = −0.37, standard deviation [SD] = 1.07), weight (M = −0.57, SD = 0.92), and BMI (M = −0.55, SD = 0.95) were below average. The SDS values for weight and BMI increased significantly between t0 and t4 with small effect sizes, whereas the SDS value for height did not. Diagnosis, gender, disease localisation, and remission after 6 months did not influence height SDS. Patients treated exclusively with enteral nutrition (EEN) or azathioprine showed improved weight and BMI development, whereas corticosteroids led to weight gain. Conclusion: The analysis showed that EEN and disease control significantly improve weight and BMI in children with IBD, SDS‐H catch‐up was only observed in the subgroup with growth impairment at initial diagnosis. Children with severe or recurrent flares, or persistent nutritional deficits, are at increased risk of growth impairment and require close medical monitoring.
SN - 0277-2116
SN - 1536-4801
ER -